luke evnin mpm capital lp profile  biography  bloomberg feedback luke evnin managing directorcofounder mpm capital lp career history managing director mpm asset management llc present general partner mpm bioventures iii lp present managing directorcofounder mpm capital lp present cofounder mpm asset mgmt investors present mpm asset management llc  general partner accel partners  accel partners  general partnercofounder mpm asset mgmt investors unknown cofounder mpm capital lp unknown show more website wwwmpmcapitalcom corporate information address  kendall street cambridge ma  united states phone  fax  web url wwwmpmcapitalcom from the web personal information education princeton university bachelors degree university of california san francisco doctorate degree biochemistry memberships board memberships peptimmune inc board member present biovalve technologies inc board member present innovative spinal technologies inc board member present neurotherapeutics pharma inc board member present syndax pharmaceuticals inc board member present oxagen ltd board member present enteromedics inc board member  pacira pharmaceuticals inc board member  metabasis therapeutics inc board member  restore medical inc board member  genome therapeutics corp board member  genesoft inc board member  sonic innovations inc board member  signal pharmaceuticals inc board member former otix global inc board member former epic therapeutics inc board member former costim pharmaceuticals inc board member former epix pharmaceuticals inc board member former intercell ag board member unknown idun pharmaceuticals inc board member unknown oscient pharmaceuticals corp board member unknown show more other memberships scleroderma research foundation chairman sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data luke evnin phd  mpm capital back to team luke evnin phd investment team san francisco office luke evnin phd cofounded mpm with ansbert gadicke in  and opened the san francisco office in  the mpm team they have led has been the inspiration and driving force behind building companies such as biomarin bmrn costim pharmaceuticals acquired by novartisnvs  epizyme epzm idenix acquired by merckmrk pacira pcrx pharmasset acquired by gileadgild and radius rdus mpm believes that these companies are among the biggest successes in biotech history – companies that ultimately resulted in helping thousands of patients live longer and with vastly improved lives luke was the lead investor and has served on the boards of several of mpm’s most successful investments including costim pharmaceuticals idun pharmaceuticals and pacira prior to cofounding mpm luke honed his skills as a venture capitalist beginning in  at accel partners where he focused on emerging healthcare companies luke’s passion for drug discovery began in college where he received his ab in molecular biology from princeton university he advanced his technical training and launched his interest in curing disease with his doctoral study in the department of biochemistry at the university of californiasan francisco luke’s passion for discovering and pushing forward groundbreaking drug discovery companies inspires his work and that of his team luke has devoted significant efforts since  to working with the scleroderma research foundation serving as chairman since  luke also devotes energy to the external advisory board at the lewissigler institute for quantitative genomics at princeton serves on the external advisory boards for qb at ucsf the masters in translational medicine program at ucsf and the boston university scleroderma cort print contact x x x mpm capital  powering breakthroughs in life sciences mpm focus area drugs for the treatmentof human viral andother infectious diseaseswatch now chris bardon md oncology impact fund discuss advances in cancer therapies bloomberg capital markets june  related investment pharmasset companies mpm investment strategy mpm capital works with leading scientists to create companies that seek to address unmet needs and change the face of medicine across all therapeutic areas mpm is currently investing out of bv its most recent venture fund in  mpm partnered with ubs to create the ubs oncology impact fund oif an innovative impact investing fund focused exclusively on oncology that will invest in both private and public equities oif will support both basic cancer research as well as access to cancer care in developing countries fund all bv oncology impact fund investments current exited exit type all ipo ma focus area all oncology other andme genetic reports for consumers to better appreciate their ancestry other current  smallmolecule therapeutics that modulate mirnas for treatment oncology current affymax inc previously committed to developing novel drugs other exited aires clinical stage pharmaceutical company for pulmonary disorders other exited alinea pharmaceuticals inc previously developed new treatments for metabolic conditions other exited allozyne inc cancer and inflammatory disease therapeutic company oncology exited alnara orallydelivered protein therapeutics to treat metabolic diseases other exited amphivena developing bispecific tandabs as a novel immunotherapy for hematological disorders oncology current anthera developing drugs for autoimmune diseases other exited aratana provides innovative therapies for companion animals other current archus orthopedics inc previously developed implants to treat spine disorders other exited aryx therapeutics inc previously focused on molecular design other exited astute medical improving the diagnosis of highrisk medical conditions other current atopix therapeutics inc developing novel treatments for asthma other exited barrier therapeutics inc specialized in dermatological creams and gels other exited biomarin innovative therapeutics to patients with serious unmet medical needs other exited blade therapeutics a discovery stage company focused on developing fibrosis treatments other current celladon developing a transformative therapy for heart failure other exited cellerant therapeutics inc novel immunotherapies for oncology and bloodrelated disorders oncology exited cerecor inc developing innovative treatments for patients with cns disorders other exited ceregene inc development and manufacturing of gene therapies other exited cerimon pharmaceuticals inc developed and commercialized therapeutics for autoimmune diseases other exited chf solutions inc manufactures medical devices for cardiac care other exited chiasma developing oral drugs that were previously only available by injection other current clinical ink modernize clinical trials with esource  patient engagement tools other current conatus developing novel therapeutics for liver diseases other exited costim developing novel antibodies for cancer immunotherapy oncology exited cotherix inc licensing of therapeutic products for cardiopulmonary diseases other exited digitx partners digital health investment partnership with astellas pharma other current dragonfly sciences inc developing a new class of biosimilar products other exited ekr therapeutics provides acutecare specialty products other exited elixir pharmaceuticals inc develops novel pharmaceuticals for the treatment of metabolic diseases other exited endogastric solutions inc endoluminal treatment of gastroesophageal reflux disease other exited endologix provides optimal solutions for endovascular aortic repair other current enteromedics inc developer of vbloc® neurometabolic therapy other current epizyme personalized therapeutics for patients with genetically defined cancer oncology current fortebio develops analytical systems that enable realtime analysis of biomolecular interactions other exited harpoon therapeutics t cell redirection to deliver deep remissions oncology current helicos biosciences corporation genetic analysis for the research drug discovery and diagnostics other exited hypnion inc development of novel therapeutics for cns disorders other exited iconic developing therapeutics for serious eye disorders other current idenix discovers and develops drugs for human viral diseases other exited idun pharmaceuticals inc other exited innovative spinal technologies inc developed treatments for spinal disorders other exited intercell ag modern prophylactic and therapeutic vaccines other exited intracel holdings corporation development and commercialization of cancer vaccines other exited iomx therapeutics ag targeting t cell evasion to treat cancer oncology current ipierian developing antitau protein antibodies for neurodegenerative disease other exited kalobios pharmaceuticals inc developing monoclonal antibodies for cancer care oncology exited macrogenics inc oncology exited maverick therapeutics inc inducible t cellredirecting antibodies oncology current memory pharmaceuticals corp developed drug candidates for the treatment of cns disorders other exited meritage pharma treatment for eosinophilic esophagitis eoe other exited mitobridge discovers and develops novel drugs that enhance mitochondrial function other current motus therapeutics inc developing therapies for severe gastric mobility disorders other exited neosil manufactures dermatologyfocused specialty pharmaceutical products other exited neovista inc technologies for age related mucular degeneration other exited neuromed pharmaceuticals inc produces pain therapies in the us other exited nevro developing a highfrequency stimulation technology for chronic pain other exited oncorus developing a nextgeneration immunotherapy platform to treat cancer oncology current oxagen limited a privatelyheld biopharmaceutical company other current pacira acute care products including exparel for postsurgical analgesia other exited peptimmune inc designs peptides for therapeutics diagnostic kits  antibodies other exited pernix therapeutics inc specialty primary care and generic medicines other exited pharmasset discovering and developing novel drugs to treat viral infections other exited pharmathene inc acquire and develop products identified as urgent priorities other exited poniard pharmaceuticals inc discovery development and commercialization of oncology products other exited portola pharmaceuticals inc a biopharmaceutical company in the hematologic diseases fields other exited potenza therapeutics developing novel immunotherapies for the treatment of cancer oncology current proteon therapeutics developing a therapy to improve dialysis vascular access other current quatrx pharmaceuticals company treatment of moderate to severe dyspareunia fda approved in feb  other exited radius health novel differentiated therapeutics for patients with osteoporosis other current raze therapeutics developing novel antitumor agents through mitochondrial onecarbon me oncology current repare therapeutics targeting geneticallydefined cancer weaknesses oncology current rhythm developing peptide therapeutics for metabolic diseases other current rigel pharmaceuticals inc smallmolecule development for inflammatory and autoimmune diseases oncology exited rinat neuroscience corp develops treatment of diseases and disorders of the nervous system other exited sai drug discovery development and manufacturing services other exited selexys developing novel products to treat inflammatory diseases other exited semma therapeutics developing cellbased transformative therapies for diabetes patients other current sideris pharmaceuticals inc development of new treatments for transfusion related iron overload other exited solasia developing commercializing oncology  oncology supportive care drugs oncology exited somaxon pharmaceuticals inc developed silenor for treatment of insomnia other exited surface logix inc enhancing molecular functionality of pharmaceuticals other exited syndax developing and commercializing epigenetic therapies for cancer oncology current tcr inc focused on engineering t cells for cancer therapy oncology current tercica inc developed increlex for treatment of primary igf deficiency other exited tetherex pharmaceuticals corporation operates in the healthcare industry focusing on biotechnology business other current theraclone sciences inc screening technology for antibodies that ward off disease other exited tizona therapeutics inc regulatory t cell suppression as a novel approach to fighting cancer oncology current trieza therapeutics immunomodulatory oncolytic virus therapeutics oncology current trinetx platform to improve clinical research study design  recruitment other current true north therapeutics developing drugs which selectively inhibit the complement system other exited vaccinogen inc personalized vaccines to fight disease oncology other current valeritas marketing a disposable insulin delivery device other current vascular developing a novel antibody for diabetic nephropathy other current verastem inc treating cancer by the targeted killing of cancer stem cells oncology exited verus pharmaceuticals inc pediatricoriented specialty pharmaceutical company other exited xanodyne pharmaceuticals inc integrated specialty pharmaceutical company other exited mpm team mpms team is comprised of innovators entrepreneurs executives  investors role investment team medical  scientific advisors operations team location all cambridge san francisco patrick baeuerle patrick baeuerle phd managing director cambridge read bio chris bardon christiana bardon md managing director cambridge read bio vinay bhaskar vinay bhaskar phd principal san francisco read bio laura brass laura brass phd mba managing director cambridge read bio lauren cauley lauren cauley chief financial officer cambridge read bio thomas ebeling thomas ebeling medical and scientific advisor oif read bio stephen elledge stephen j elledge phd medical and scientific advisory board mpm  oif read bio luke evnin luke evnin phd managing director san francisco read bio mitchell finer phd mitchell finer phd managing director cambridge read bio todd foley todd foley mba managing director cambridge read bio shinichiro fuse shinichiro fuse phd principal cambridge read bio ansbert gadicke ansbert gadicke md managing director cambridge read bio bard geesaman bard geesaman md phd managing director cambridge read bio william greene william greene md venture partner san francisco read bio william hahn william c hahn md phd medical and scientific advisor oif read bio dan hicklin dan hicklin phd managing director cambridge read bio robert horvitz h robert horvitz phd medical and scientific advisory board mpm  oif read bio ed hurwitz ed hurwitz jd mba managing director san francisco read bio briggs morrison briggs morrison md managing director cambridge read bio vas narasimhan vas narasimhan md medical and scientific advisory board mpm read bio gary patou gary patou md managing director san francisco read bio sarah reed sarah reed chief operating officer and general counsel cambridge read bio tony rosenberg tony rosenberg managing director cambridge read bio david ryan david p ryan md medical  scientific advisor oif read bio kazumi shiosaki kazumi shiosaki phd managing director cambridge read bio greg sieczkiewicz greg sieczkiewicz jd phd managing director  chief ip counsel cambridge read bio elizabeth stoner elizabeth stoner md managing director cambridge read bio chris varma chris varma phd entrepreneurinresidence cambridge read bio contact us infompmcapitalcom cambridge ma  kendall street cambridge ma  phone   see full map  get directions san francisco ca  gateway boulevard suite  south san francisco ca  phone   see full map  get directions print terms of use  disclosures  july   radius health appoints jesper høiland as president and chief executive officer leading the next stage of growth and value creation as a fully integrated commercial biotech company june   semma therapeutics mentioned in wsj article “biotech startups’ cellbased diabetes attack” june   mpm and versant venture colead series a financing of repare therapeutics june   proteon therapeutics announces  million private placement june   visionary scientist stephen j elledge joins mpm capital’s medical and scientific advisory board june   accomplished oncologist and scientist william c hahn joins mpm capital’s oncology impact fund advisory board june   tcr therapeutics to debut positive solid tumor data on its novel truc™ engineered t cell platform at the world preclinical congress june   radius presents positive data from a fully enrolled ongoing phase i study for investigational drug elacestrant rad at the  american society of clinical oncology annual meeting asco may   amgen vet patrick baeuerle inspires a m round from alist vcs for a nextgen io drug platform may   harpoon therapeutics announces completion of m series b financing may   mpm portfolio company true north therapeutics acquired by bioverativ inc upfront payment of m plus assumed cash with additional payments of up to m contingent on the achievement of future milestones may   syndax shares soar as lead drug clears a midstage cancer drug study hurdle may   conatus announces exercise of license option for global development and commercialization of emricasan following notice of initiation of phase b encorelf clinical trial in nash cirrhosis may   inside perspectives on cancer immunotherapy an interview with mpm’s christiana bardon april   fda approves mpm portfolio company radius health’s tymlos™ abaloparatide bone building agent for the treatment of postmenopausal women with osteoporosis at high risk for fracture april   meet one the most successful german biotech leaders ever read more about mpm’s patrick baeuerle april   mpm managing director chris bardon named a top transformer top innovation gurus leading the biopharma industrys transformation are recognized by mmm april   mpm portfolio company oncorus nominated for  nevy award as hottest earlystage startup therapeutics april   syndax pharmaceuticals adds biopharmaceutical industry leader keith a katkin to board of directors february   rhythm announces completion of  million mezzanine financing — proceeds to finance significant expansion of genetic obesity clinical trials — february   chris varma cofounder and former president and ceo of blueprint medicines joins mpm as entrepreneurinresidence january   mpm portfolio company maverick therapeutics and takeda announce fiveyear collaboration to advance tcell engagement therapies january   accomplished biotech investor ed hurwitz joins mpm as managing director  december   mpm portfolio company astute medical forms strategic partnership with biotechne december   novartis signs exclusive option collaboration and license agreement with mpm portfolio company conatus pharmaceuticals inc december   oncorus® inc announces additional series a financing support from astellas venture management llc december   harpoon therapeutics appoints gerald mcmahon phd as president and ceo december   tcr therapeutics launches from stealth mode to accelerate development of novel cancer immunotherapies  m series a financing led by mpm capital and f ventures  december   chris bardon mpm managing director comments to bloomberg on new approaches to medical philanthropy read full article – “a few billionaires are turning medical philanthropy on its head” november   epizyme announces fast track designation for tazemetostat in dlbcl and provides tumor program update november   novartis acquires mpm portfolio company selexys pharmaceuticals corporation and selg antibody for reduction of pain crises in sickle cell disease november   harpoon therapeutics appoints hanspeter gerber phd as chief scientific officer november   semma therapeutics announces mark fishman md has joined its board of directors as chairman october   mpm portfolio company epizyme expands clinical programs through cooperative research and development agreements with the national cancer institute october   motus therapeutics inc a subsidiary of mpm portfolio company rhythm holding co llc is to be acquired by allergan acquisition announced following positive results for phase b clinical trial of treatment for gi disorders october   true north therapeutics announces  million series d financing financing follows encouraging interim clinical data announced for lead product candidate tnt in cold agglutinin disease october   true north therapeutics receives fda orphan drug designation for tnt for the treatment of autoimmune hemolytic anemia including cold agglutinin disease cad october   pacira pharmaceuticals’ kristen williams is honored as  of  “fierce women in biopharma ” learn why kristen stands out among women in the industry september   iomx therapeutics raises eur  million in series a round company establishes toptier investor base consisting of mpm capital sofinnova partners wellington partners and merck ventures september   three mpm portfolio companies blade oncorus  rhythm named to fiercebiotech’s “ fierce ” list september   radius announces publication of additional positive results from the phase  active trial of osteoporosis treatment september   tizona therapeutics inc appoints george golumbeski phd to its board of directors august   osteoporosis a disease with few treatment options may soon have one more read coverage in ny times and in press release august   aratana secures third fda approval animal pain drug expected to be available to veterinarians in the fall of  august   harvard medical school appoints mpm medical and scientific advisory cochair george daley as new dean read more in the boston globe august   iconic therapeutics announces final close of series c financing with additional  million investment august   astellas and mpm capital launch digitx partners july   mpm portfolio company blade therapeutics featured in the san francisco business times the july  article “taking it personally cutting–edge biotech snags  million” discusses the latest round of funding for blade a company focused on finding therapies for fibrotic disease and mpm cofounder luke evnin’s personal commitment to the cause july   rhythm announces new england journal of medicine publication of setmelanotide phase  data for treatment of pomc deficiency obesity significant weight loss with targeted treatment for patients with rare genetic defect in critical weight regulation pathway july   former bluebird bio blue cso takes the reins at oncorus startup launches with  million series a june   mpm portfolio company semma therapeutics featured in boston globe bostonarea hospitals have teamed up with the harvard stem cell institute and semma therapeutics to make personalized cellbased therapies and organize clinical trials june   chris bardon managing director for the oncology impact fund on bloomberg capital markets discussing advances in cancer therapies as the  asco annual meeting gets underway may   trinetx enters into collaboration with celgene advance clinical trial design and research for nextgeneration medicines planned may   aratana therapeutics granted fda approval of entyce® firstofitskind ghrelin mimetic may   mpm launches  million social impact oncology fund april   ubs cancer fund shows power of impact investing a new oncology fund will finance academic research and access to cancer care in developing countries april   ubs mpm seek big ‘impact’ in cancer drugs with m fund by marie powers bioworld today april   april   ubs raises record  million for oncology impact fund biospacecom  march   aratana therapeutics granted first fda approval galliprant for the control of pain and inflammation associated with osteoarthritis in dogs march   chiasma initiates phase  trial to support european registration of octreotide capsules for patients with acromegaly march   tizona therapeutics inc completes  million series b financing march   radius health submits new drug application to the us food and drug administration for abaloparatidesc for the treatment of postmenopausal women with osteoporosis march   nasdaq welcomes syndax parmaceuticals inc to the nasdaq stock market january   iconic therapeutics closes series c financing  october   cerecor announces pricing of initial public offering october   semma therapeutics named fiercemedicaldevices’  fierce  august   syndax enters clinical trial collaboration in cancer immunotherapy combining entinostat and atezolizumab august   syndax raises  million in series c financing august   rhythm subsidiary raises  million in oversubscribed financing financing to advance rhythm metabolic incs setmelanotide program for rare genetic disorders of obesity august   epizyme appoints robert bazemore president and chief executive officer july   chiasma inc prices initial public offering of common stock july   taking clinical trials out of the dark ages clinical ink june   briggs w morrison md ceo of syndax appointed key strategic advisor to mpm capital june   chiasma submits new drug application to us fda for octreotide capsules in acromegaly submission based on positive results from phase  clinical trial june   k peter hirth phd joins iconic therapeutics as board member and senior scientific advisor may   mpm capital appoints pablo j cagnoni md former onyx pharmaceuticals president as managing director and ceo of mpm immunotherapy portfolio company vesuvius may   mpm closes  million fund may   andme launches the lupus research study in collaboration with pfizer inc with lupus awareness month underway study aims to build a patient lupus cohort to advance understanding of the disease april   astellas pharma and potenza therapeutics partner to build a portfolio of immunooncology therapeutics exclusive collaboration includes option for astellas to acquire potenza april   novartis international global head ma and licensing anthony rosenberg to join as managing director effective april    to serve as strategic advisor and on mpm portfolio boards to build leading companies  march   biotech startup to fight diabetes on the cellular front semma therapeutics seeks to turn success in stem research lab into a way to encourage insulin production march   semma therapeutics announces  million in funding led by mpm capital to develop cell therapy for treating type  diabetes signs agreement with global pharmaceutical company march   ebb  flow chiasma’s private decision march   chiasma announces mark leuchtenberger as chief executive officer proven business leader to oversee commercialization of octreotide capsules march   andme to create therapeutics group appoints scientific luminary rd executive richard scheller phd to lead dr scheller joins andme’s executive leadership team as chief science officer and head of therapeutics march   mpm capital announces immunooncology pioneer patrick baeuerle to serve as managing director top scientist and drug developer joins mpm senior team advancing breakthroughs and discoveries march   radius rdus announced today that it has acquired the license to develop and market rad in japan dinesh purandare hired former sanofi sanpa oncology executive to the position of senior vice president svp and head of global oncology at radius  february   chiasma announces completion of  million series e financing february   verastem receives orphan drug designation from fda for vs in mesothelioma february   chiasma appoints david stack as chairman of the board john a scarlett md joins board of directors february   syndax says immunooncology discovery happened instead of an ipo february   chiasma inc releases newly published phase  study results show positive outcomes for octreotide capsules in people with acromegaly a serious hormonal disorder february   radius celladon and nevro among top ipos in  mpm has   and  out of the top  january   radius the top performing ipo of  radius which is developing treatments for osteoporosis is up  since pricing its june  initial public offering at   december   radius announces positive phase  topline results december   for venture capital biotech is where it’s really at august   aratana featured startups work on biotech drugs for pets july   cerecor inc closes on initial tranche of usm series b financing june   true north snags m and sets course for the clinic with a rare disease drug april   ipierian acquired by bristolmyers squibb advances discovery strategy to pursue therapeutics for genetically defined diseases april   iconic therapeutics raises  million to advance clinical development of wet amd program william greene md appointed chief executive officer april   celladon receives breakthrough therapy designation from fda mydicar is first gene therapy reported to receive breakthrough designation from fda’s center for biologics evaluation and research cber february   costim pharmaceuticals inc acquired by novartis january   mpm capital and kleiner perkins caufield  byers top the list of investors with the most  ipos january   epizyme and celgene advance epz dotl inhibitor clinical program to benefit cancer patients with acute leukemias achieving  million clinical proof of concept milestone     x x x   forbidden access is denied server error   forbidden access is denied you do not have permission to view this directory or page using the credentials that you supplied luke evnin mpm capital lp lse lifescienceseuropecom  the european life sciences web portal zum inhalt home about us contact news people products deals organisations » follow us on twitter » get free newsletter top news gsk appoints laurie glimcher as noneexecutive director leo pharma eu approves kyntheum brodalumab in psoriasis lundbeck invests in trevis� m series c financing round oryzon to regain rights to ory rg from roche spindiag gmbh raises �m seed round from private investors » more news » submit your news   upcoming events berlin conference on life sciences  citi�s th annual biotech conference  boston basel life  embo � miptec msacl  eu salzburg morgan stanley global healthcare conference  new york boaml global healthcare conference  london hupo  dublin th annual world congress smash  nmr conference baveno italy european biotech week  biopharm america  boston sachs annual biotech in europe forum  basel asebio investor day  barcelona european business development conference  heidelberg ebdc  worldlab  durban cphi worldwide  frankfurt » more events » submit your event   bio regions  life sciences clusters biopro badenw�rttemberg gmbh flandersbio vzw scanbalt network scanbalt fmba biosaxony e v germany trade and invest � gesellschaft f�r au�enwirtschaft und standortmarketing mbh medicon valley alliance mva life science austria lisa service unit of austria wirtschaftsservice gmbh one nucleus mediwales ci cluster cluster f�r individualisierte immunintervention e v » more clusters and regions » submit your cluster or region   business parks  science centres izb innovations und gr�nderzentrum biotechnologie martinsried f�rdergesellschaft izb mbh genopole gip genopole technologiepark heidelberg gmbh parc cientific de barcelona bcp barcelona science park foundation campus vienna biocenter association vbc medeon science park oxford science park the leiden bio science park foundation biocity nottingham ltd london bioscience innovation centre lbic » more business parks » submit your business park   associations europabio � the european association of bioindustries bioindustry association bia gb emerging biopharmaceutical enterprises ebe france biotech asebio spanish bioindustry association bio deutschland e v european bioeconomy alliance eba » more associations » submit your association   partners » media partners » become a partner   advertisement person › detailsluke evnin mpm capital lpevnin luke mpm capital  managing director  organisation mpm capital lp   group mpm capital group product venture capital   product  life sciences           record changed  advertisement to subscribe to our free monthly newsletter for the european life sciences please send an email to infoiitode and simply fill the subject line with the word �lse newsletter� to get even more information please take a look at our gs professional services offering and read the genesensor product flyer pdf file advertisement » top advertisements � imprint    � contact    the use of this website requires to accept the disclaimer     a project of iito business intelligence   made in germany insider trading  evnin luke  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  evnin luke select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing option award  pm na syndax pharmaceuticals inc sndx evnin lukedirector owner   direct view other  pm nana radius health inc rdus evnin lukeother   indirect view conversion  pm nana syndax pharmaceuticals inc sndx evnin lukedirector owner   indirect view conversion  pm nana syndax pharmaceuticals inc sndx evnin lukedirector owner   indirect view conversion  pm nana syndax pharmaceuticals inc sndx evnin lukedirector owner   indirect view conversion  pm nana syndax pharmaceuticals inc sndx evnin lukedirector owner   indirect view conversion  pm nana syndax pharmaceuticals inc sndx evnin lukedirector owner   indirect view conversion  pm nana syndax pharmaceuticals inc sndx evnin lukedirector owner   indirect view conversion  pm nana cerecor inc cerc mpm bioventures v lpmpm asset management investors bv llcmpm bioventures v gp llcmpm bioventures v llcgadicke ansbertevnin lukekailian vaughn mscopa james paulfoley todd owner   indirect view conversion  pm nana cerecor inc cerc mpm bioventures v lpmpm asset management investors bv llcmpm bioventures v gp llcmpm bioventures v llcgadicke ansbertevnin lukekailian vaughn mscopa james paulfoley todd owner   indirect view conversion  pm nana chiasma inc chma mpm bioventures iv qp lpevnin lukescopa james paulkailian vaughn mmpm asset management investors bv llcmpm bio iv nvs strategic fund lpmpm bioventures iv gmbh  co beteiligungs kgmpm bioventures iv gp llcmpm bioventures iv llc owner   indirect view conversion  pm nana chiasma inc chma mpm bioventures iv qp lpevnin lukescopa james paulkailian vaughn mmpm asset management investors bv llcmpm bio iv nvs strategic fund lpmpm bioventures iv gmbh  co beteiligungs kgmpm bioventures iv gp llcmpm bioventures iv llc owner   indirect view conversion  pm nana chiasma inc chma mpm bioventures iv qp lpevnin lukescopa james paulkailian vaughn mmpm asset management investors bv llcmpm bio iv nvs strategic fund lpmpm bioventures iv gmbh  co beteiligungs kgmpm bioventures iv gp llcmpm bioventures iv llc owner   indirect view conversion  pm nana chiasma inc chma mpm bioventures iv qp lpevnin lukescopa james paulkailian vaughn mmpm asset management investors bv llcmpm bio iv nvs strategic fund lpmpm bioventures iv gmbh  co beteiligungs kgmpm bioventures iv gp llcmpm bioventures iv llc owner   indirect view conversion  pm nana chiasma inc chma mpm bioventures iv qp lpevnin lukescopa james paulkailian vaughn mmpm asset management investors bv llcmpm bio iv nvs strategic fund lpmpm bioventures iv gmbh  co beteiligungs kgmpm bioventures iv gp llcmpm bioventures iv llc owner   indirect view conversion  pm nana chiasma inc chma mpm bioventures iv qp lpevnin lukescopa james paulkailian vaughn mmpm asset management investors bv llcmpm bio iv nvs strategic fund lpmpm bioventures iv gmbh  co beteiligungs kgmpm bioventures iv gp llcmpm bioventures iv llc owner   indirect view conversion  pm nana chiasma inc chma mpm bioventures iv qp lpevnin lukescopa james paulkailian vaughn mmpm asset management investors bv llcmpm bio iv nvs strategic fund lpmpm bioventures iv gmbh  co beteiligungs kgmpm bioventures iv gp llcmpm bioventures iv llc owner   indirect view conversion  pm nana chiasma inc chma mpm bioventures iv qp lpevnin lukescopa james paulkailian vaughn mmpm asset management investors bv llcmpm bio iv nvs strategic fund lpmpm bioventures iv gmbh  co beteiligungs kgmpm bioventures iv gp llcmpm bioventures iv llc owner   indirect view   secformcom all rights reserved archives        mon  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  board of directors  amphivena home about us leadership board of directors scientific advisory board rd partnerships newsmedia contact us board of directors luke evnin phd jeanmarie guenot phd florian fischer ph d luke evnin phd luke evnin is managing director of mpm capital a venture firm dedicated to life sciences investing dr evnin cofounded mpm’s asset management business in  to launch mpm’s first venture fund and established the san francisco office for the firm in  previously dr evnin was at accel partners for over seven years including four as a general partner  at accel partners he was involved in biopharmaceutical medical device and healthcare service companies for accel’s funds iii iv and v dr evnin earned his phd in the department of biochemistry at the university of californiasan francisco and he received his ab in molecular biology magna cum laude from princeton university he serves on the external advisory board for qb the advisory board for mission bay capital the internal venture investment vehicle for qb the external advisory board for the lewis sigler institute of quantitative genomics at princeton and is the chairman of the scleroderma research foundation  jeanmarie guenot phd president and ceo jeanmarie guenot phd has over  years of experience in the pharmaceutical and biotechnology industry she has worked with all stages of companies both public and private in pharmaceutical rd corporate  commercial development business development project  alliance management and venture capital she has significant expertise and interest in building or rebuilding companies and is currently the president  ceo of amphivena therapeutics inc a company that is developing innovative bifunctional antibody therapies for hematologic malignancies prior to her current role dr guenot founded built and ran sks ocular a startup ophthalmic company incubator focused on dry amd sustained release ocular drug delivery technologies and therapeutics for glaucoma macular degeneration and ocular inflammation  she was a business advisor for hoffmannla roche in basel and shanghai and she was vice president of corporate  business development at pdl biopharma where she led licensing mergers and acquisitions and alliance management for pdl’s rd and commercial product portfolios  she led and negotiated the biogen idecpdl  codevelopment and cocommercialization strategic collaboration which involved three phase  cancer and autoimmune disease drug candidates  this  m transaction included a  m equity investment in pdl and a therapeutic candidate with indications split between biogen idecpdl and hoffmannla roche   she also licensed the ophthalmic indication for the oncology drug to ophthotech  she has portfolio project and alliance management experience in the areas of oncology cardiovascular diseases autoimmune diseases neurology and ophthalmic diseases dr guenot started her business career at atlas venture where she managed venture capital investments and built life science companies  she started her scientific career as a principal scientist in preclinical rd at hoffmannla roche discovering and developing drugs for metabolic diseases inflammation autoimmune diseases and oncology  dr guenot trained in physical and medicinal chemistry with a focus in quantum mechanical and semiempirical methods for molecular dynamics protein structure prediction xray and nmr refinement and drug design  she earned her phd from the university of california san francisco and her mba from the wharton school at the university of pennsylvania florian fischer ph d dr fischer joined affimed in  as cfo on a parttime basis since september  dr fischer is fulltime employed by affimed he has a strong track record in various biotechmedtech executive positions as lead advisor in a variety of transactions and financings in the life sciences and healthcare sector dr fischer is founder of medventure partners – a corporate finance and strategy advisory company focusing on the life sciences and healthcare industry dr fischer was chief financial officer of activaero gmbh from  until  and responsible for corporate development until the acquisition by vectura in  he also served as chief financial officer of vivendy ltd from  until  and as managing director of abcheck in  prior to founding medventure partners dr fischer worked with kpmg for more than six years until  where he was responsible for biotech and healthcare assignments before joining kpmg he worked for deutsche bank ag dr fischer is also a director of amphivena he holds a graduate degree in business administration from humboldt university berlin and a phd in public health from the university of bielefeld restoring the flow of life home leadership board of directors rd partnerships newsmedia contact us copyright  amphivena therapeutics inc all rights reserved  san francisco web design by thomas digital board of directors  amphivena home about us leadership board of directors scientific advisory board rd partnerships newsmedia contact us board of directors luke evnin phd jeanmarie guenot phd florian fischer ph d luke evnin phd luke evnin is managing director of mpm capital a venture firm dedicated to life sciences investing dr evnin cofounded mpm’s asset management business in  to launch mpm’s first venture fund and established the san francisco office for the firm in  previously dr evnin was at accel partners for over seven years including four as a general partner  at accel partners he was involved in biopharmaceutical medical device and healthcare service companies for accel’s funds iii iv and v dr evnin earned his phd in the department of biochemistry at the university of californiasan francisco and he received his ab in molecular biology magna cum laude from princeton university he serves on the external advisory board for qb the advisory board for mission bay capital the internal venture investment vehicle for qb the external advisory board for the lewis sigler institute of quantitative genomics at princeton and is the chairman of the scleroderma research foundation  jeanmarie guenot phd president and ceo jeanmarie guenot phd has over  years of experience in the pharmaceutical and biotechnology industry she has worked with all stages of companies both public and private in pharmaceutical rd corporate  commercial development business development project  alliance management and venture capital she has significant expertise and interest in building or rebuilding companies and is currently the president  ceo of amphivena therapeutics inc a company that is developing innovative bifunctional antibody therapies for hematologic malignancies prior to her current role dr guenot founded built and ran sks ocular a startup ophthalmic company incubator focused on dry amd sustained release ocular drug delivery technologies and therapeutics for glaucoma macular degeneration and ocular inflammation  she was a business advisor for hoffmannla roche in basel and shanghai and she was vice president of corporate  business development at pdl biopharma where she led licensing mergers and acquisitions and alliance management for pdl’s rd and commercial product portfolios  she led and negotiated the biogen idecpdl  codevelopment and cocommercialization strategic collaboration which involved three phase  cancer and autoimmune disease drug candidates  this  m transaction included a  m equity investment in pdl and a therapeutic candidate with indications split between biogen idecpdl and hoffmannla roche   she also licensed the ophthalmic indication for the oncology drug to ophthotech  she has portfolio project and alliance management experience in the areas of oncology cardiovascular diseases autoimmune diseases neurology and ophthalmic diseases dr guenot started her business career at atlas venture where she managed venture capital investments and built life science companies  she started her scientific career as a principal scientist in preclinical rd at hoffmannla roche discovering and developing drugs for metabolic diseases inflammation autoimmune diseases and oncology  dr guenot trained in physical and medicinal chemistry with a focus in quantum mechanical and semiempirical methods for molecular dynamics protein structure prediction xray and nmr refinement and drug design  she earned her phd from the university of california san francisco and her mba from the wharton school at the university of pennsylvania florian fischer ph d dr fischer joined affimed in  as cfo on a parttime basis since september  dr fischer is fulltime employed by affimed he has a strong track record in various biotechmedtech executive positions as lead advisor in a variety of transactions and financings in the life sciences and healthcare sector dr fischer is founder of medventure partners – a corporate finance and strategy advisory company focusing on the life sciences and healthcare industry dr fischer was chief financial officer of activaero gmbh from  until  and responsible for corporate development until the acquisition by vectura in  he also served as chief financial officer of vivendy ltd from  until  and as managing director of abcheck in  prior to founding medventure partners dr fischer worked with kpmg for more than six years until  where he was responsible for biotech and healthcare assignments before joining kpmg he worked for deutsche bank ag dr fischer is also a director of amphivena he holds a graduate degree in business administration from humboldt university berlin and a phd in public health from the university of bielefeld restoring the flow of life home leadership board of directors rd partnerships newsmedia contact us copyright  amphivena therapeutics inc all rights reserved  san francisco web design by thomas digital luke evnin levnin  twitter skip to content home home home current page about search query search twitter searches you follow follow following unfollow saved searches remove in this conversation verified accountprotected tweets  suggested users verified accountprotected tweets  verified accountprotected tweets  language english bahasa indonesia bahasa melayu català čeština dansk deutsch english uk español filipino français hrvatski italiano magyar nederlands norsk polski português română slovenčina suomi svenska tiếng việt türkçe ελληνικά български език русский српски українська мова עִבְרִית العربية فارسی मराठी हिन्दी বাংলা ગુજરાતી தமிழ் ಕನ್ನಡ ภาษาไทย 한국어    have an account log in have an account remember me · forgot password new to twitter sign up luke evnin levnin tweets tweets current page  following following  followers followers  likes likes    more likes unmute levnin mute levnin follow following unfollow blocked unblock pending cancel luke evnin levnin venture capital investor chairman scleroderma research foundation san francisco ca srfcureorg joined may   photos and videos photos and videos tweets tweets tweets current page tweets  replies you blocked levnin are you sure you want to view these tweets viewing tweets wont unblock levnin yes view profile close luke evnin followed luke evnin retweeted srfcure‏ srfcure  aug  more copy link to tweet embed tweet join srfcure and support lisa helfand and take sclerodermaselfies join the movement httpbitlyivclnv  today pm ct  reply  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo luke evnin‏ levnin  jul  more copy link to tweet embed tweet stupidest product that is now available you might buy it by accident dawn infused bounty paper towels please a plea for common sense  replies  retweet  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo luke evnin‏ levnin  jun  more copy link to tweet embed tweet still enjoying the high from incredible coolcomedyhotcuisinethank u bob sagetjmayerjgaffiganjgarlinjkimmel sfenigerscleroderma  replies  retweets  like reply  retweet retweeted like  liked  thanks twitter will use this to make your timeline better undo luke evnin‏ levnin  jun  more copy link to tweet embed tweet watching jeff rosshe is a courageous comedian raosting nazis in jail and his compassion shows through realjeffrefyross  replies  retweets  likes reply retweet retweeted like  liked  thanks twitter will use this to make your timeline better undo luke evnin‏ levnin  may  more copy link to tweet embed tweet tom with your push i got myself on the service interesting notes will have to keep up and find that  bottle luke  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo levnin hasnt tweeted yet back to top ↑ loading seems to be taking a while twitter may be over capacity or experiencing a momentary hiccup try again or visit twitter status for more information new to twitter sign up now to get your own personalized timeline sign up you may also like · refresh false   twitter about help center terms privacy policy cookies ads info close choose a trend location dismiss close previous next close go to a persons profile searches you follow follow following unfollow saved searches remove in this conversation verified accountprotected tweets  suggested users verified accountprotected tweets  verified accountprotected tweets  close promote this tweet close block cancel block add a location to your tweets when you tweet with a location twitter stores that location you can switch location onoff before each tweet and always have the option to delete your location history learn more turn location on not now close share location results from send close your lists close create a new list list name description under  characters optional privacy public · anyone can follow this list private · only you can access this list save list close close copy link to tweet heres the url for this tweet copy it to easily share with friends close embed this tweet embed this video add this tweet to your website by copying the code below learn more add this video to your website by copying the code below learn more hmm there was a problem reaching the server try again include parent tweet include media by embedding twitter content in your website or app you are agreeing to the twitter developer agreement and developer policy preview close why youre seeing this ad close log in to twitter remember me · forgot password dont have an account sign up » close sign up for twitter not on twitter sign up tune into the things you care about and get updates as they happen sign up have an account log in » close twoway sending and receiving short codes country code for customers of united states  any canada  any united kingdom  vodafone orange  o brazil  nextel tim haiti  digicel voila ireland  vodafone o india  bharti airtel videocon reliance indonesia  axis  telkomsel indosat xl axiata italy  wind  vodafone » see sms short codes for other countries close confirmation close   close skip all welcome home this timeline is where you’ll spend most of your time getting instant updates about what matters to you tweets not working for you hover over the profile pic and click the following button to unfollow any account say a lot with a little when you see a tweet you love tap the heart — it lets the person who wrote it know you shared the love spread the word the fastest way to share someone else’s tweet with your followers is with a retweet tap the icon to send it instantly join the conversation add your thoughts about any tweet with a reply find a topic you’re passionate about and jump right in learn the latest get instant insight into what people are talking about now get more of what you love follow more accounts to get instant updates about topics you care about find whats happening see the latest conversations about any topic instantly never miss a moment catch up instantly on the best stories happening as they unfold back next next tweet from user